Circulating Dopamine and C-Peptide Levels in Fasting Nondiabetic Hypertensive Patients

The Graz Endocrine Causes of Hypertension study

Andreas Tomaschitz, MD
Eberhard Ritz, MD
Katharina Kienreich, MD
Burkert Pieske, MD
Winfried Marz, MD

Bernhard O. Boehm, MD
Christiane Drechsler, MD, PhD
Andreas Meinitzer, PhD
Stefan Pilz, MD

OBJECTIVE—Accumulating evidence supports a potential role for dopamine in the regulation of insulin secretion. We examined the association between circulating dopamine and C-peptide concentrations using data from the Graz Endocrine Causes of Hypertension (GECOH) study.

RESEARCH DESIGN AND METHODS—After 12 h of fasting, we measured plasma dopamine and serum C-peptide levels and established determinants of insulin secretion in 201 nondiabetic hypertensive patients (mean age 48.1 ± 16.0 years; 61.7% women).

RESULTS—Mean dopamine and C-peptide concentration were 33.4 ± 38.6 pg/mL and 3.1 ± 2.7 ng/mL, respectively. A strong and inverse correlation was observed between dopamine and C-peptide levels (r = −0.423, P < 0.001). There was no significant relationship between C-peptide, plasma epinephrine, and norepinephrine. C-peptide levels decreased steadily and significantly from tertile 1 of dopamine (3.6 ng/mL [95% CI 2.9–4.1]) to tertile 3 (1.6 ng/mL [1.5–2.7], P < 0.001) after multivariate adjustment.

CONCLUSIONS—The inverse association between dopamine and C-peptide highlights the need to evaluate whether dopamine could be effective for modulating endocrine pancreatic function.

Diabetes Care 35:1771–1773, 2012

Circulating dopamine is 1) derived from sympathetic noradrenergic nerves and 2) synthesized within the adrenal medulla and in amine precursor uptake and decarboxylation cells (i.e., in the kidney and endocrine pancreas) (1).

Accumulating evidence supports a role for catecholamines in the regulation of insulin secretion (2). Lerner and Porte (3) observed the inhibitory effects of epinephrine (and norepinephrine) on the acute pancreatic insulin response to glucose but not during prolonged hyperglycemia. Animal studies documented an inhibition of pancreatic insulin secretion in response to dopamine administration (4). Mice lacking D2 dopamine receptors showed an impaired glucose–related insulin release, which results in glucose intolerance (5).

In view of the evidence for the inhibitory effects of dopamine on insulin secretion, we hypothesize that circulating dopamine is inversely related to C-peptide levels, reflecting prehepatic insulin secretion, in fasting nondiabetic adult hypertensive patients (6).

RESEARCH DESIGN AND METHODS—The Graz Endocrine Causes of Hypertension (GECOH) study population comprises adult diabetic and nondiabetic patients (aged ≥18 years), who have routinely been referred to our outpatient clinic for screening for endocrine hypertension (6). Between February 2009 and November 2011, 224 white study participants were enrolled. Main inclusion criterion was arterial hypertension. The exclusion criteria have been described in the published study protocol (6). Patients taking antipsychotic drugs and/or with a diagnosis of psychosis or Cushing’s disease, which are both known to have impact on dopamine and insulin secretion, were excluded from the analysis. Finally, after exclusion of 23 patients with diabetes (0.9% with type 1 diabetes and 9.4% with type 2 diabetes, classified according to American Diabetes Association criteria), 201 participants remained eligible for the analysis (7). Blood samplings were performed in the morning (8:00–11:00 A.M.) after the patients had been seated for 10 min.

Extensive laboratory and clinical assessments were performed after at least 12 h of fasting. Written informed consent was obtained from all study participants. The GECOH study complies with the Declaration of Helsinki.

Laboratory methods

The laboratory methods have been described in detail in a previous report (6). Measurement of plasma dopamine concentrations was performed using a radioimmunoassay
Circulating dopamine and C-peptide levels

Epinephrine and norepinephrine were determined by the TriCat-RIA (reference limit <100 and <600 pg/mL, respectively). Serum C-peptide concentrations were determined by a chemoluminescence sandwich immunnoassay (ADVIA Centaur; Siemens Healthcare Diagnostics, Tarrytown, NY).

Statistical analysis

Pearson correlation analyses were performed to analyze the associations between circulating C-peptide, dopamine, epinephrine, and norepinephrine levels. One-way ANCOVA followed by Bonferroni post hoc tests was used to compare mean C-peptide values across sex-specific tertiles of the dopamine concentration after consideration of age, BMI, HbA1c, fasting glucose, triglycerides, LDL cholesterol, HDL cholesterol, serum albumin, C-reactive protein, systolic blood pressure, glomerular filtration rate, epinephrine, norepinephrine, serum cortisol, active smoking, regular alcohol consumption, and detailed antihypertensive medication and statin use as potential confounders. All data were analyzed using the SPSS software package (version 17.0; SPSS, Chicago, IL). P < 0.05 was considered statistically significant.

RESULTS

The mean age of the 201 nondiabetic hypertensive white study participants (61.7% women) was 48.1 ± 16.0 years. Plasma dopamine concentration was 33.4 ± 38.6 pg/mL, and serum C-peptide concentration was 3.1 ± 2.7 ng/mL.

Pearson correlation analysis revealed a strong and inverse association between C-peptide and dopamine concentrations (r = −0.42, P < 0.001). Sex-stratified subgroup analysis revealed a strong correlation between C-peptide and dopamine in either sex (Fig. 1A and B). No significant correlation was seen between C-peptide and norepinephrine (r = 0.06, P = 0.198) and epinephrine (r = −0.05, P = 0.196) levels. Circulating dopamine correlated positively with norepinephrine levels (r = 0.19, P = 0.022). A strong positive correlation was seen between the insulin-to-C-peptide molar ratio (mean 0.07 ± 0.04 pmol/L:pmol/L) and plasma dopamine (r = 0.30, P < 0.001), although this association might be mainly attributed to the strong correlation between C-peptide and dopamine. Only borderline significance was found between serum insulin and dopamine (r = −0.16, P = 0.057).

In fully adjusted ANCOVA, we noted a significant decrease in C-peptide values (P < 0.001) across increasing values of dopamine concentration (in sex-specific tertiles) in the entire cohort. The absolute mean difference in C-peptide levels between dopamine concentration tertile 1 (3.6 ng/mL) and tertile 3 (1.6 ng/mL) was 2.0 ng/mL.

CONCLUSIONS

We demonstrate that higher dopamine levels are strongly related to lower serum C-peptide values in plasma of 12-h postabsorptive nondiabetic hypertensive patients. The inverse association between C-peptide and dopamine persisted after consideration of multiple confounders. The present observation implicates a potential role for peripheral dopamine in modulating insulin secretion and β-cell function in fasting conditions.
There has been growing interest in the impact of dopamine on insulin secretion. Studies in healthy volunteers revealed increased insulin levels after dopamine administration, but these studies were limited by small sample size (8,9). Rubi et al. (10) identified D2 dopamine receptors, which are activated by extracellular (circulating) dopamine, in insulin granules of human β-cells. Activation of these receptors results in an inhibition of glucose-related cell membrane depolarization and insulin exocytosis (4,5,10). Shankar et al. (10) demonstrated that insulin secretion is stimulated at low and inhibited at high dopamine concentrations. These studies therefore, by the majority, support our findings. However, in contrast to previous studies, we neither observed lower dopamine levels nor a weaker association between dopamine and C-peptide levels in diabetic compared with nondiabetic participants (data not shown) (11).

In line with our findings, several human studies documented metabolic alterations by neuroleptic drugs as a result of interference with dopaminergic pathways (12). Several but not all studies documented that the use of the dopamine agonist, bromocriptine, is paralleled by decreased insulinemia (13–15).

We found no association between plasma norepinephrine and serum C-peptide levels. This finding points to dopamine but not to norepinephrine as a major mediator of insulin secretion. Because dopamine, serum cortisol, epinephrine, and norepinephrine clearly were below the upper reference limit, we suggest that our findings are not primarily triggered by an increased stress response.

Although blood was drawn after a 10-min period in the sitting position, we cannot conclude that this resting period was adequate to reliably interpret circulating dopamine levels. In addition, we analyzed nondiabetic hypertensive white subjects; therefore, generalizations to other populations cannot be made. The observational study design precludes conclusions with regard to causal relationships.

In summary, higher circulating dopamine is independently related to lower serum C-peptide. Additional studies are warranted to delineate the effects of dopamine on insulin secretion.

Acknowledgments—A.T. is partially funded by the European Union Project MASCARA (Markers for Sub-Clinical Cardiovascular Risk Assessment; THEME HEALTH 2011.2.4.2-2; Grant 278249). K.K. is supported by funding from the Austrian National Bank (Jubiläumsfond: Projects 13878 and 13905).

No potential conflicts of interest relevant to this article were reported.

A.T. and S.P. wrote the manuscript, researched data, and are the principal investigators. E.R. reviewed and edited the manuscript. K.K. researched data and reviewed and edited the manuscript. B.P., W.M., B.O.B., C.D., and A.M. reviewed and edited the manuscript and contributed to the discussion. A.T. and S.P. are the guarantors of this work and, as such, had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank the whole staff of the outpatient clinic and the laboratory at the Department of Endocrinology and Metabolism at the Medical University of Graz for supporting them with the GECOH study.

References
1. Goldstein DS, Holmes C. Neuronal source of plasma dopamine. Clin Chem 2008;54:1864–1871
2. Quickel KE Jr, Feldman JM, Lebovitz HE. Inhibition of insulin secretion by serotonin and dopamine: species variation. Endocrinology 1971;89:1295–1302
3. Lerner RL, Porte D Jr. Epinephrine: selective inhibition of the acute insulin response to glucose. J Clin Invest 1971;50:2453–2457
4. Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005;280:36824–36832
5. Garcia-Tornadi I, Ornstein AM, Chamon-Reig A, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010;151:1441–1450
6. Piltz S, Tomaschitz A, Stepan V, et al. Graz Endocrine Causes of Hypertension (GECOH) Study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 2009;9:11
7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62–S67
8. Martin G, Forte P, Luchinger A, et al. Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients. J Clin Pharmacol 1994;34:91–94
9. Ruttimann Y, Schutz Y, Jéquier E, Lemarchand T, Chiolero R. Thermogenic and metabolic effects of dopamine in healthy men. Crit Care Med 1991;19:1030–1036
10. Shankar E, Santhosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 2006;58:157–163
11. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol 2010;79:1827–1836
12. Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277–290
13. Pijl H, Obashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23:1154–1161
14. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667–670
15. Wasada T, Kawahara I, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000;23:1039–1040